DTC
FDMT icon

Deep Track Capital’s 4D Molecular Therapeutics FDMT Stock Holding History

Deep Track Capital’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-609,900
Closed -$3.4M – 71
2024
Q4 		$3.4M Sell
609,900
-3,486,552
-85% -$27.4M 0.13% 60
2024
Q3 		$44.3M Buy
4,096,452
+35,051
+0.9% +$582K 1.4% 25
2024
Q2 		$85.2M Buy
4,061,401
+1,026,948
+34% +$25.8M 2.54% 15
2024
Q1 		$96.7M Buy
3,034,453
+750,081
+33% +$19.1M 2.77% 16
2023
Q4 		$46.3M Sell
2,284,372
-493,735
-18% -$6.5M 1.55% 26
2023
Q3 		$35.4M Hold
2,778,107
– – 1.37% 26
2023
Q2 		$50.2M Buy
2,778,107
+500,000
+22% +$9.21M 2.32% 16
2023
Q1 		$39.2M Sell
2,278,107
-378,794
-14% -$7.37M 1.61% 23
2022
Q4 		$59M Sell
2,656,901
-539,741
-17% -$8.34M 2.48% 14
2022
Q3 		$25.7M Buy
3,196,642
+56,642
+2% +$513K 1.18% 34
2022
Q2 		$21.9M Buy
3,140,000
+691,800
+28% +$6.73M 1.44% 25
2022
Q1 		$37M Buy
2,448,200
+548,200
+29% +$8.61M 2.37% 16
2021
Q4 		$41.7M Buy
+1,900,000
New +$46.6M 2.94% 11

Other funds holding FDMT

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Deep Track Capital's FDMT Position: Q1 2025 in Review

Deep Track Capital sold out of 4D Molecular Therapeutics (FDMT) in Q1 2025, closing a stake of 609,900 shares — an estimated $3.4M sold.

Deep Track Capital first reported a position in FDMT in Q4 2021 and held it in 13 quarters. The position peaked at $96.7M in Q1 2024. 125 funds tracked by Wall St. Rank hold FDMT as of Q1 2025.

  • Deep Track Capital reported no remaining 4D Molecular Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Deep Track Capital sold 609,900 4D Molecular Therapeutics shares in Q1 2025, an estimated $3.4M.
  • Deep Track Capital first reported a position in 4D Molecular Therapeutics in Q4 2021 and held it in 13 quarters.
  • Deep Track Capital's 4D Molecular Therapeutics position peaked at $96.7M in Q1 2024.
  • 125 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2025.

Based on Deep Track Capital's 13F filing for Q1 2025, filed 15 May 2025.